Abstract: A non-cytotoxic chlorine dioxide composition and a mixed agent bleaching composition for tooth whitening are disclosed. Methods of use are also provided.

Abstract: The present invention relates to an implantable paste comprising bioactive glass spheres having a size distribution of 50-425 ?m, low molecular weight polyethylene glycol having a molecular weight range of 200-700 g/mol, medium molecular weight polyethylene glycol having a molecular weight range of 700-2500 g/mol and high molecular weight polyethylene glycol having a molecular weight range of 2500-8000 g/mol, with the proviso that the molecular weight of the low molecular weight polyethylene glycol and of the medium molecular weight polyethylene glycol differ from each other by at least 80 g/mol and that the molecular weight of the medium molecular weight polyethylene glycol and of the high molecular weight polyethylene glycol differ from each other by at least 300 g/mol.

Abstract: Oxygen therapy for healthy or inflamed but intact skin involves placing an oxygen-generating dressing onto the skin to be treated, the oxygen-generating bandage being a one-time use dressing capable of generating oxygen for only a short period of time, not to exceed about 4 hours.

Abstract: Provided are formulations comprising therapeutically effective amounts of ambrisentan or a pharmaceutically acceptable salt thereof and tadalafil or a pharmaceutically acceptable salt thereof and methods of treating and/or preventing pulmonary hypertension by administration of the formulations.

Abstract: Provided are methods for treating inflammatory neurodegenerative diseases (e.g., multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, stroke/cerebral ischemia, head trauma, spinal cord injury, Huntington's disease, migraine, cerebral amyloid angiopathy, inflammatory neurodegenerative condition associated with AIDS, age-related cognitive decline; mild cognitive impairment and prion diseases in a mammal), or at least one symptom thereof in a subject by administering a therapeutic composition comprising at least one electrokinetically-altered fluids (e.g., electrokinetically-generated oxygen-enriched fluids) of the present invention. Particular aspects provide methods for inhibiting and/or modulating the function and/or activity of effector T-cells, and/or for cell-based tolerogenic therapy (e.g., by modulating development and/or function and/or activity of TREG cells and/or dendritic cells (DCs) and/or TH17 cells (e.g., ROR?t+ TH17 cells).

Abstract: A multi-part kit system comprising a solid part A which comprises at least one acetyl donor, a liquid part B in the form of an aqueous composition which comprises 3 to 35 wt. % of hydrogen peroxide and one or more parts C, wherein the solid part A and/or the part(s) C comprise at least one surfactant selected from the group consisting of anionic surfactants, amphoteric surfactants and nonionic surfactants, wherein the composition of the parts of the multi-part kit system is such, that directly after being mixed with each other and water in a specified ratio the pH of the mixture is in the range of 5.5 to 8.

Abstract: A perfluorocarbon gel composition is disclosed with numerous uses including topical medical and cosmetic uses.

Abstract: The presently disclosed subject matter provides methods for increasing perfusion in hypoxic regions of tissues in subjects. Also provided are methods for treating diseases and/or disorders associated with hypoxia in subjects, methods for increasing sensitivity of tumors to radiation and/or chemotherapy treatments, methods for delaying tumor growth in subjects, and methods for inhibiting tumor blood vessel growth in subjects. In some embodiments, the presently disclosed methods involve administering to subjects in need thereof a first composition selected from the group consisting of a nitrosylated hemoglobin and an agent that induces nitrosylation of endogenous hemoglobin in the subject and a second composition comprising a hyperoxic gas. In some embodiments, the presently disclosed methods also include treating a tumor with radiation therapy, chemotherapy, photodynamic therapy, immunotherapy, or combinations thereof. Also provided are inhalable gases that can be employed in the presently disclosed methods.

Abstract: The use of gaseous oxygen for the production of a therapeutic gas for inhalation by a patient who has been identified as a person with a mitochondrial disorder or a coenzyme Q10 deficiency, for the treatment of mitochondrial disorders or Q10 deficiencies is disclosed. For the first time a non-invasive method is disclosed, upon what the body's own level of Q10 can be raised significantly without further interventions.

Abstract: A method for antimicrobial treatment (e.g. antimicrobial treatment of food packaging and equipment) comprising applying to microbes a composition containing a diluting solvent (e.g., water), an antimicrobially-active solvent having a density different from the density of the diluting solvent, and an optional cosolvent, surfactant, or additional antimicrobial agent, wherein the amount of antimicrobially-active solvent or additional antimicrobial agent is sufficiently high and the amount of cosolvent or surfactant is sufficiently low so that the composition will provide greater than a 1-log order reduction in the population of bacteria or spores of Bacillus cereus within 10 seconds at 60° C. Preferred methods of the invention employ compositions containing an additional antimicrobial agent such as peroxyacetic acid. Compositions for use in the method can be prepared as concentrates, and used full strength or in diluted form.

Abstract: There is disclosed a skincare composition suitable for topical application to the skin. The composition comprises salicylic acid or a salt thereof and hydrolysed milk protein. The composition is useful in the treatment of acne.

Abstract: Compositions for producing a biocide solution upon contact with water, the composition comprises at least an acid anhydride and polyoxychlorine donor. The biocide solution forms reactive oxygen species that releases oxygen gas when contacted by microorganisms, proteinaceous substances, and oxidizable organic based contaminants. The biocide solution is free of chlorine dioxide.

Abstract: Compositions and their use for treating bacterial infections are described, in particular compositions for treating multi-species infections and the treatment of bacterial infections arising from biofilms. The present invention also relates to antibacterial compositions for treating dental diseases. Compositions of the present invention may include a garlic extract or S-allyl cysteine, and optionally an antibiotic and/or an antiseptic.

Abstract: A method for rejuvenating a reverse osmosis (RO) membrane which is subject to biofilm and other contaminants in an aqueous system through the use of a free molecular iodine solution at a pH of about 2.2 to 4.0.

Abstract: Compositions containing a carrier and microbubbles encapsulating one or more gases, preferably oxygen, and methods for making and using the compositions are described herein. The microbubbles contain a lipid envelope. The compositions may be administered to a patient to quickly deliver large amounts of oxygen to the patient's blood supply or directly to a tissue in need of oxygen. The compositions may be administered via injection or as a continuous infusion. The compositions contain a concentrated microbubble suspension, where the suspension contains at least 40 mL oxygen/dL suspension. The microbubbles are preferably less than 20 microns in diameter, more preferably less than 15 microns in diameter. The microbubbles described herein may be administered to a patient in an effective amount to increase in oxygen concentration in the patient's blood, and/or one or more tissues or organs.

Abstract: Dispersing gas in a liquid provides a mixture of saturated, supersaturated or hypersaturated solution to provide a suspension of bubbles containing gas therein into which animal tissue is immersed for health or wellness treatment. A two-phase mixture is provided with dissolved gas as a suspension of microbubbles. Methods for making, maintaining, and using the two-phase mixture are provided. Gas molecules may be introduced into a liquid at high velocity under elevated pressure to form a supersaturated solution that retains the gas, preferably oxygen, in solution when exposed to ambient conditions.

Abstract: The invention relates to a gaseous mixture containing oxygen (O2) and a volume proportion of 20 to 70% of xenon (Xe) for use as an inhalable drug for preventing or treating hypersensitivity to pain in humans or animals, in particular hypersensitivity to pain expressed as hyperalgesia or allodynia.

Abstract: Provided are methods for protecting against or reducing neurotoxicity of exposure to a neurotoxic agent, comprising administering an electrokinetically altered aqueous fluid as provided herein in an amount sufficient to provide for neuroprotection against the neurotoxic agent, preferably where protecting against or reducing loss of motor coordination in the subject exposed to the neurotoxin is afforded. In certain aspects, protecting or reducing neurotoxin-mediated neuronal apoptosis is afforded, and/or activating or inducing at least one of PI-3 kinase and Akt phosphorylation in neurons is afforded. Preferably, administering the fluid comprises administering the fluid prior to exposure to the neurotoxic agent.

Abstract: A composite for delivering extended-release of oxygen is disclosed. The composite can include a biocompatible polymeric support having a plurality of solid peroxide particles suspended therein. The polymer support can exhibit an oxygen tension value of at least 40 mmHg for a period of 14 days. The weight ratio of biocompatible polymeric support to solid peroxide particles can range from 1:1 to 99:1. Also disclosed is a method of using the composite to deliver oxygen to cells in both in vivo and in vitro environments.

Abstract: Disclosed is a sterilizing catalyst, a sterilizing device and a sterilizing system, the sterilizing catalyst includes a metal lattice including a metal oxide, and an oxygen vacancy-inducing metal that is integrated or encompassed within the metal lattice. The metal oxide is an oxide of a divalent or multivalent metal. The oxygen vacancy-inducing metal has an oxidation number lower than that of the divalent or multivalent metal.

Abstract: An object of the present invention is to provide a medical agent that has an excellent effect on the diseases resulting from one of inflammation and remodeling and that can prevent or treat them in response to various mechanisms of onset and development of the diseases. Thus, the present invention relates to a medical agent for preventing or treating diseases resulting from one of inflammation and remodeling in blood vessel, including nanobubbles.

Abstract: The present invention relates to an ozone water that has the potential to find useful applications in a wide variety of technical fields and is capable of maintaining the effects of wiping out microorganisms such as bacteria, viruses and the like and inhibiting the growth thereof over long periods. The present invention provides ozone nano-bubbles capable of staying in a solution for an extended period of time and a method for producing the ozone nano-bubbles by instantaneously shrinking the diameters of ozone microbubbles contained in an aqueous solution by the application of a physical irritation to the ozone microbubbles in an aqueous solution.

Abstract: Compositions, kits and methods for promoting diabetic wound healing are based on the discovery that SDF-1? specifically upregulates expression of E-selectin in mature endothelial cells (EC), leading to an increase in EC-endothelial progenitor cell (EPC) adhesion and EPC homing. Methods for promoting healing of a wound in a diabetic subject include providing a therapeutically effective amount of a composition including E-selectin protein or a nucleic acid encoding E-selectin protein, and optionally, an agent that specifically upregulates E-selectin expression (e.g., SDF-1?). The methods can also include administering hyperbaric oxygen treatment to the subject. Administering the composition to the subject results in migration of bone marrow-derived progenitor cells to the wound, accelerated wound healing, and upregulation of E-selectin expression in the subject.

Abstract: Liquid medicaments incorporate about 1.0-3.0% active benzoyl peroxide (BP) by weight in substantially fully solubilized form, while being substantially free of acetone and other harsh, dermatologically undesirable solvents. The novel compositions are produced by (a) creating an emulsion or slurry of BP in an emollient, topically acceptable ester, and (b) dissolving the emulsion or slurry in absolute alcohol. The medicaments may be used in the treatment of BP-responsive skin conditions in mammals, e.g., acne vulgaris or rosacea. The novel medicaments may be dispensed directly to the affected skin area through the use of an applicator device comprising a fluid reservoir associated with a foam applicator tip, or via a spray dispenser, atomizer or pump spray.

Abstract: The present application relates to the use of helium-oxygen gas mixtures for the treatment and/or prophylaxis of primary and secondary forms of pulmonary hypertension (PH) and also to the combination of drugs and helium-oxygen gas mixtures, wherein the gas mixtures are used as carrier gases to improve the introduction of a drug for the treatment and/or prophylaxis of pulmonary hypertension.

Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.

Abstract: A method for oxygenating a fluid, the method including launching a sub-orbital lower-level apparatus to a predetermined altitude greater than 20,000 feet above sea level. The method also includes, at the predetermined altitude, actuating a fluid capture mechanism sealingly configured to collect and store an atmospheric fluid. In addition, returning the a sub-orbital lower-level apparatus to an altitude less than 20,000 feet, and introducing at least a portion of the atmospheric fluid to an oxygenation process to mix the captured atmospheric fluid with another fluid.

Abstract: In this disclosure, methods and systems for drug delivery utilizing high shear are disclosed. In an embodiment, a method comprises (1) subjecting a therapeutic fluid containing a drug to high shear; and (2) obtaining a processed therapeutic fluid, wherein the processed therapeutic fluid contains the drug in nano-size. In an embodiment, a method comprises (1) subjecting a drug carrier and a therapeutic fluid containing a drug to high shear; and (2) obtaining a processed therapeutic fluid, wherein the processed therapeutic fluid contains the drug carrier loaded with the drug. In an embodiment, a method comprises (1) applying high shear to a drug carrier and a therapeutic fluid containing a drug; (2) obtaining a processed therapeutic fluid, wherein the processed therapeutic fluid contains the drug-loaded carrier; and (3) modifying the drug-loaded carrier with a targeting moiety to obtain a modified drug-loaded carrier.

Abstract: The present invention describes systems and methods to provide variable flow oxygen therapy. An exemplary embodiment of the present invention provides a method of oxygen therapy involving delivering oxygen-enriched gas to a patient during a first portion of a breathing cycle at a first flow rate. Furthermore, the method of oxygen therapy involves delivering oxygen-enriched gas to the patient during a second portion of the breathing cycle at a second flow rate, where the second flow rate is greater than zero and less than the first flow rate.

Abstract: A medicinal drug is administered to a person for treating a medical condition of the person or/and for preventing the person from contracting the medical condition. The medical condition can be a bacterial infection, a eukaryotic infection, a prion-caused infection, a non-pathogenic inflammation, and, insofar as not covered by any of these four types of the medical condition, a fungal infection, a spore-caused infection, and a parasitic infection. A medicinal drug is similarly administered non-topically to a person for treating a virus-caused medical condition of the person or/and for preventing the person from contracting the virus-caused medical condition. The medicinal drug is typically formed at least partially with salt of peroxymonosulfuric acid, preferably potassium hydrogen peroxymonosulfate.

Abstract: The invention relates to compositions, implantable devices and methods related to tissue engineering. Provided is a composition comprising (i) at least one biocompatible polymer suitable for use in tissue-engineering scaffolds and (ii) at least one metal peroxide. Also provided is an implantable device comprising said composition, and methods for tissue engineering comprising the use of the device.

Abstract: The invention relates to new antimicrobial compositions comprising a combination of—at least one organic and/or inorganic peroxide, —at least one silver source, and —at least one nitrogen containing compound which is a non glucogenic compatible solute, selected from taurine, choline and choline derivatives, trimethylamine-oxide (TMAO), ectoine and hydroxyectoine, the N-methylated aminoacids glycine betaine, dimethylglycine, sarcosine, carnitine, N-methyl alanine, trimethylamino-butyric acid, butyrobetaine and proline betaine, and the poly amino hydrocarbon compounds putrescine, cadaverine, spermine and spermidine.

Abstract: A method for treating a patient comprising: (a) injecting into the bloodstream of a patient is breathing a gas mixture having greater than 25% oxygen an aqueous solution comprising: 0.1 to 0.8 M Mg++ and having an osmolarlity less than about 1500 mOSm/l; and (b) increasing the rate of injection at least until the patient feels a sensation of warmth is described.

Abstract: The invention discloses methods and devices for promotion of skin healing, skin conditioning and skin rejuvenation for skin and tissue repair. More specifically, the invention is directed toward the manufacture of a storable therapeutic pad containing a therapeutic solution within a matrix. The therapeutic solution is produced by mixing oxygen with a fluid such as normal saline using an ultrasound station. Alternatively, the matrix may be composed of gels, solids and fibrous materials. The ultrasound station can be used to form micro-bubbles containing oxygen which allow storage of relatively high quantities of oxygen in a storage container containing the therapeutic pad. Micro-bubbles may be attached to stands or contained within a closed-cell foam. At the appropriate time, the storage container is opened and the therapeutic pad is attached to the wound site. The therapeutic pad is held between an impermeable layer and the wound site with an adhesive layer.

Abstract: The present invention refers to a pharmaceutical preparation for treating inflammatory diseases and microbial infections comprising a pharmaceutically effective amount of ozone and at least one monomeric amino acid having an oxidation-sensitive side chain, or at least one ozonized monomeric amino acid having an oxidation-sensitive side chain. Also described is the use of a preparation as described before for providing a medicament for treating inflammatory diseases, microbial infections and for immune modulation. The pharmaceutical preparation according to the invention is particularly useful in the treatment of oral inflammations.

Abstract: A method for treating a patient comprising: (a) injecting into the bloodstream of a patient is breathing a gas mixture having greater than 25% oxygen an aqueous solution comprising: 0.1 to 0.8 M Mg++ and having an osmolarlity less than about 1500 mOSm/l; and (b) increasing the rate of injection at least until the patient feels a sensation of warmth is described.

Abstract: Provided are electrokinetically-altered fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating a wound to a surface tissue or a symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g.

Abstract: A detergent and disinfectant in which water-soluble permanganates are used in an alkaline solution in order to initiate the oxidation of organic substances and simultaneously a chemical oxidant, preferably a peroxodisulfate, is used which is capable of producing radical reactions with catalytic support by manganates originating from the supplied permanganate, which reactions produce the oxidation of organic substances. All components are present in powder form and a respective powder mixture can be dissolved rapidly and free from residues in water. It thus represents a universally applicable, highly effective detergent and disinfectant.

Abstract: The invention relates to a method for enriching water with oxygen by an electrolytic process, that comprises the following series of steps: the electrolysis of Cl? Br? ion-free water in an electrolysis cell in which the anode and the cathode are separated by a gas-tight membrane that is pervious to electric charges; b) recovering the oxygen-enriched water from the anode compartment of the electrolysis cell.

Abstract: This invention relates to methods and pharmaceutical compositions for regulating the levels of proinflammatory substances released from activated microglia using a protein kinase C delta (PKCd) inhibitor. In particular, it relates to decreasing the levels of proinflammatory substances produced within the microglial cells or released from activated microglical cells or both. Accordingly, the invention provides for the treatment of diseases, disorders, and conditions where neuroinflammation is implicated. The invention also relates to methods of using PKCd inhibitors and pharmaceutical compositions to treat diseases, disorders, and conditions associated with activated microglia.

Abstract: One aspect of the invention relates to substitute quinolines with antimalarial activity, and compositions and kits comprising at least one of them. Another aspect of the invention relates to methods for the treatment or prevention or both of malaria comprising administering to a subject a therapeutically effective amount of such a compound. Importantly, a number of the compounds show excellent potency against both chloroquine-sensitive and chloroquine-resistant strains.

Abstract: The present invention provides a method for preventing or repairing damage to a fetal membrane. In one embodiment, the method comprises contacting a fetal membrane with a composition comprising a four-armed catechol-terminated polyethylene glycol (cPEG) and a biocompatible oxidant. In one embodiment, the four-armed cPEG and the biocompatible oxidant are initially contained in separate solutions, and the solutions are mixed to form the composition just prior to or at the same time that the composition contacts the fetal membrane.

Abstract: An electrochemically treated solution and method for cut flower and plant preservation, the solution having potassium, hypochlorous acid, and dissolved oxygen.

Abstract: A system and method for generating an oxygen enriched aqueous solution for therapeutic application includes a diffuser comprising a first diffusing member having a surface incorporating surface disturbances, and a second diffusing member positioned relative to the first diffusing member to form a channel through which an aqueous solution and oxygen gas may flow. A reservoir containing the aqueous solution is connected to a pump that draws the aqueous solution from the reservoir and inputs the aqueous solution into the diffuser. The aqueous solution is moved through the channel relative to the surface disturbances to create cavitation in the aqueous solution to diffuse the oxygen gas into the aqueous solution to produce an oxygen enriched aqueous solution.

Abstract: Methods of treating cardiovascular diseases, including atherosclerosis, peripheral arterial occlusive disease, congestive heart failure, hypertension, cerebrovascular disease, dyslipidemia and vasospastic disorders such as Raynaud's disease, in a mammalian patient involve extracorporeally subjecting an amount of blood, blood fractionate or other biological fluid from a patient to a measured amount of ozone delivered by an ozone delivery system, resulting in the absorption of a quantifiable absorbed-dose of ozone and reinfusing the treated fluid into the patient to therapeutically treat cardiovascular disease and related conditions.

Abstract: Methods for therapeutic treatment of inflammatory conditions in a mammalian patient provide clinical benefits including reduction of inflammation, vasorelaxation, reduction in edema and increased blood flow, the methods generally comprising extracorporeal treatment of blood, blood fractionate, or other biological fluid to expose such fluids to a precise, measured amount of ozone to produce a blood or biological fluid having a quantified absorbed dose of ozone, and reinfusing the treated biological fluid to the patient to provide therapeutic effects beneficial in the treatment of inflammatory disorders and related symptoms or conditions.

Abstract: Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient for treating an inflammatory neurodegenerative condition or disease (e.g., multiple sclerosis (MS), Parkinson's disease (PD), Alzheimer's disease (AD)) or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential and/or conductance, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes).

Abstract: A system for reducing or preventing the growth of organisms in the process water used to coat glass fibers with a formaldehyde-free binder composition. One or more biocides is added to the process water that mitigates the growth of microbes in the water. The biocides are added in an amount sufficient to minimize growth of organisms without adversely affecting the application of the binder composition to the glass fibers.

Abstract: Provided are electrokinetically-altered aqueous fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating an irritation, infection or inflammatory eye condition, comprising administering to, by contacting the eye of a subject in need thereof a therapeutically effective amount of an electrokinetically-altered aqueous fluid. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g.

Abstract: This invention relates generally to compositions for whitening human teeth, and more particularly, to compositions that do not contain hydrocarbon humectants and which, when applied onto the surface of teeth act to whiten without damage to tooth surfaces. They do contain a hydrogel, defined as a gel that does not contain a hydrocarbon humectant. A hydrocarbon humectant is defined as a carbon, hydrogen and oxygen compound which is used to prevent the oral care composition from hardening upon exposure to air or a carbon, hydrogen and oxygen compound which is used as a carrier for ingredients of an oral care composition.